Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Sales | 24,808 | 24,987 | 43,484 | 59,590 | 45,663 |
| Cost of Goods | 3,147 | 2,405 | 3,858 | 2,955 | 1,460 |
| Gross Profit | 21,661 | 22,582 | 39,626 | 56,635 | 44,203 |
| Operating Expenses | 26,966 | 27,117 | -786,059 | 24,441 | 21,301 |
| Operating Income | -5,158 | -4,130 | 826,543 | 33,149 | 23,362 |
| Interest Expense | 8,993 | 9,012 | 8,906 | 20,142 | 11,200 |
| Other Income | -5,720 | -4,886 | 25,076 | -69,794 | 67,064 |
| Pre-tax Income | -19,871 | -18,028 | 842,713 | -56,787 | 79,226 |
| Income Tax | -4,620 | -3,609 | 176,376 | -14,307 | 11,864 |
| Net Income Continuous | -15,251 | -14,419 | 666,337 | -42,480 | 67,362 |
| Net Income | $-15,251 | $-14,419 | $666,337 | $-42,480 | $67,362 |
| EPS Basic Total Ops | -0.81 | -0.74 | 32.59 | -2.00 | 3.19 |
| EPS Basic Continuous Ops | -0.81 | -0.74 | 32.59 | -2.00 | 3.19 |
| EPS Diluted Total Ops | -0.81 | -0.74 | 31.32 | -1.66 | 2.80 |
| EPS Diluted Continuous Ops | -0.81 | -0.74 | 31.32 | -1.67 | 2.80 |
| EBITDA(a) | $9,495 | $6,091 | $838,449 | $53,573 | $35,840 |